FI943445A0 - Vesiliukoisten teksafyriinien metallikomplekseja - Google Patents

Vesiliukoisten teksafyriinien metallikomplekseja

Info

Publication number
FI943445A0
FI943445A0 FI943445A FI943445A FI943445A0 FI 943445 A0 FI943445 A0 FI 943445A0 FI 943445 A FI943445 A FI 943445A FI 943445 A FI943445 A FI 943445A FI 943445 A0 FI943445 A0 FI 943445A0
Authority
FI
Finland
Prior art keywords
water
metal complexes
soluble
soluble texaphyrins
texaphyrins
Prior art date
Application number
FI943445A
Other languages
English (en)
Swedish (sv)
Other versions
FI943445A (fi
FI107157B (fi
Inventor
Jonathan L Sessler
Gregory W Hemmi
Tarak D Mody
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of FI943445A publication Critical patent/FI943445A/fi
Publication of FI943445A0 publication Critical patent/FI943445A0/fi
Application granted granted Critical
Publication of FI107157B publication Critical patent/FI107157B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Laminated Bodies (AREA)
  • Conductive Materials (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
FI943445A 1992-01-21 1994-07-20 Menetelmä terapeuttisesti käyttökelpoisten vesiliukoisten teksafyriinien metallikompleksien valmistamiseksi FI107157B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/822,964 US5252720A (en) 1989-03-06 1992-01-21 Metal complexes of water soluble texaphyrins
US82296492 1992-01-21
US9300107 1993-01-07
PCT/US1993/000107 WO1993014093A1 (en) 1992-01-21 1993-01-07 Metal complexes of water soluble texaphyrins

Publications (3)

Publication Number Publication Date
FI943445A FI943445A (fi) 1994-07-20
FI943445A0 true FI943445A0 (fi) 1994-07-20
FI107157B FI107157B (fi) 2001-06-15

Family

ID=25237423

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943445A FI107157B (fi) 1992-01-21 1994-07-20 Menetelmä terapeuttisesti käyttökelpoisten vesiliukoisten teksafyriinien metallikompleksien valmistamiseksi

Country Status (15)

Country Link
US (9) US5252720A (fi)
EP (1) EP0623134B1 (fi)
JP (1) JP3530529B2 (fi)
KR (1) KR100286963B1 (fi)
AT (1) ATE227291T1 (fi)
AU (1) AU664877B2 (fi)
CA (1) CA2127530C (fi)
DE (1) DE69332469T2 (fi)
DK (1) DK0623134T3 (fi)
ES (1) ES2185627T3 (fi)
FI (1) FI107157B (fi)
NO (1) NO301828B1 (fi)
NZ (1) NZ246795A (fi)
PT (1) PT623134E (fi)
WO (1) WO1993014093A1 (fi)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5567687A (en) * 1989-03-06 1996-10-22 University Of Texas Texaphyrins and uses thereof
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5162509A (en) * 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5543514A (en) * 1989-12-21 1996-08-06 Board Of Regents, The University Of Texas System Water-soluble sapphyrins
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
US5457195A (en) * 1989-12-21 1995-10-10 Board Of Regents, The University Of Texas System Sapphyrin derivatives and conjugates
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5595726A (en) * 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5763172A (en) * 1992-01-21 1998-06-09 Board Of Regents, The University Of Texas System Method of phosphate ester hydrolysis
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
US5565552A (en) * 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5798491A (en) * 1993-06-09 1998-08-25 Board Of Regents, The University Of Texas System Multi-mechanistic chemical cleavage using certain metal complexes
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
ATE215839T1 (de) * 1994-03-21 2002-04-15 Dusa Pharmaceuticals Inc Pflaster und steuereinrichtung für photodynamische therapie von dermalen verletzungen
US5969111A (en) * 1994-04-14 1999-10-19 Board Of Regents, The University Of Texas System Texaphyrins substituted with imidazole are provided
AU733805C (en) * 1994-06-13 2001-12-13 Unilever Plc Bleach activation
BR9507984A (pt) * 1994-06-13 1997-11-18 Unilever Nv Catalisador de alvejamento e de oxidação e composição alvejante
US5530122A (en) * 1994-08-23 1996-06-25 Pharmacyclics, Inc. Method of isolating texaphyrins
US5633354A (en) * 1994-09-21 1997-05-27 Pharmacyclics, Inc. Phosphoramidite derivatives of texaphyrins
US5837866A (en) * 1994-09-21 1998-11-17 Board Of Regents, The University Of Texas Phosphoramidite derivatives of macrocycles
US6095147A (en) * 1994-12-01 2000-08-01 The Regents Of The University Of California Method for photo-altering a biological system to improve biological effect
US5703230A (en) * 1994-12-02 1997-12-30 University Of British Columbia Meso-monoiodo-substituted tetramacrocyclic compounds and methods for making and using the same
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US5591422A (en) * 1995-06-02 1997-01-07 Pharmacyclics, Inc. Texaphyrin complexes having improved functionalization
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins
JPH11511168A (ja) 1995-08-17 1999-09-28 モンサント カンパニー 窒素含有大環状リガンドの金属錯体の生体分子結合体を使用する診断造影検査方法
JPH11514971A (ja) * 1995-08-17 1999-12-21 モンサント カンパニー 窒素含有大環状リガンドの金属錯体を使用する診断造影検査方法
EP0862432A4 (en) 1995-09-06 2003-03-19 Univ New York State Res Found TWO-PHOTON CONVERTERING DYES AND THEIR APPLICATIONS
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US5883246A (en) * 1996-03-07 1999-03-16 Qlt Phototherapeutics, Inc. Synthesis of polypyrrolic macrocycles from meso-substituted tripyrrane compounds
US5955586A (en) * 1996-03-22 1999-09-21 Sessler; Jonathan L. Highly boronated derivatives of texaphyrins
WO1997035617A1 (en) * 1996-03-26 1997-10-02 Pharmacyclics, Inc. Use of a texaphyrin in photodynamic therapy of pigment-related lesions
US6375930B2 (en) 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
US6022959A (en) * 1996-08-20 2000-02-08 Pharmacyclics, Inc. Nucleic acids internally-derivatized with a texaphyrin metal complex and uses thereof
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
EP1091742A4 (en) 1997-02-14 2007-05-30 Miravant Pharm Inc PHOTOSENSITIVE INDIUM, FOR TPD
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US5886173A (en) * 1997-07-30 1999-03-23 Pharmacyclics, Inc. Metallation of macrocycles with 2,4-dicarbonyl-metal complexes
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
US20020155999A1 (en) * 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
JP2003500174A (ja) 1999-05-27 2003-01-07 フアルマシア・コーポレーシヨン スーパーオキシド・ジスムターゼ模倣体で修飾された生体材料
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
WO2001051087A2 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
US6949620B2 (en) * 2000-01-26 2005-09-27 Japan Science And Technology Corporation Polymeric micellar structure
JP2003535208A (ja) * 2000-06-08 2003-11-25 ラ ホヤ ファーマシューティカル カンパニー 高分子量ポリエチレン・オキシドを含む多価プラットホーム分子
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
WO2002017925A1 (en) * 2000-08-30 2002-03-07 Pharmacyclics, Inc. Non-symmetric tripyrrannes in the synthesis of novel macrocycles
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
CA2450370A1 (en) * 2001-06-11 2002-12-19 Jody Mesaros Accelerators for increasing the rate of formation of free radicals and reactive oxygen species
WO2002101847A2 (en) * 2001-06-12 2002-12-19 University Of Florida Method and device for producing near-infrared radiation
CN1615129A (zh) * 2001-12-13 2005-05-11 环状药物公司 影响神经病学进展的方法
US6984734B2 (en) 2002-02-26 2006-01-10 Board Of Regents, The University Of Texas System Cyclo[n]pyrroles and methods thereto
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
WO2004050716A2 (en) * 2002-12-04 2004-06-17 Pharmacyclics, Inc. Preparation of metallotexaphyrins
JP2006510669A (ja) * 2002-12-06 2006-03-30 アルコン，インコーポレイテッド 眼障害および眼疾患の処置のためのスーパーオキシドジスムターゼ模倣物
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US20050118102A1 (en) * 2003-04-28 2005-06-02 Intematix Corporation Spin resonance heating and/or imaging in medical applications
US20050196466A1 (en) * 2004-03-02 2005-09-08 Pharmacyclics, Inc. Process for inhibiting cell proliferation
EP1765163A1 (en) * 2004-05-20 2007-03-28 Pharmacyclics, Inc. A method of enhancing visualization of atherosclerotic plaque
US20060171845A1 (en) * 2005-01-31 2006-08-03 Dakota Technologies, Inc. Sensors for measuring analytes
EP1848466A4 (en) * 2005-01-31 2012-11-21 Yeda Res & Dev MRI CONTRAST AGENTS FOR DIAGNOSIS AND PROGNOSIS OF TUMORS
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
WO2006116021A2 (en) * 2005-04-22 2006-11-02 Intematix Corporation Mri technique based on electron spin resonance and endohedral contrast agent
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
WO2007059329A2 (en) * 2005-11-16 2007-05-24 Pharmacyclics, Inc. Methods and compositions for treating cancer
WO2007109290A2 (en) * 2006-03-20 2007-09-27 Pharmacyclics, Inc. Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
JP5237949B2 (ja) * 2006-08-18 2013-07-17 アバクス ディアグノスティカ オイ 発光性ランタノイド標識試薬及びその用途
US8133474B2 (en) * 2006-09-15 2012-03-13 Massachusetts Institute Of Technology Sensors for fluorescence and magnetic resonance imaging
ES2454974T3 (es) * 2007-06-27 2014-04-14 The General Hospital Corporation Aparato para la inhibición óptica de la terapia fotodinámica
WO2009006075A2 (en) * 2007-06-29 2009-01-08 Board Of Regents, The University Of Texas System Functionalized expanded porphyrins
CZ2007599A3 (cs) * 2007-08-31 2009-03-11 Vysoká škola chemicko-technologická v Praze Použití multimodálních systému pro prípravu prípravku k lécbe a diagnostikování nádorových onemocnení
JP5579618B2 (ja) * 2007-12-07 2014-08-27 プラナ バイオテクノロジー リミティッド 治療および診断用化合物
US8835104B2 (en) * 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
US8802074B2 (en) 2008-11-26 2014-08-12 Board Of Regents, The University Of Texas System Polymers functionalized with ion-specific recognition elements
US9599591B2 (en) 2009-03-06 2017-03-21 California Institute Of Technology Low cost, portable sensor for molecular assays
WO2011140561A1 (en) * 2010-05-07 2011-11-10 Molycorp Minerals Llc Lanthanide-mediated photochemical water splitting process for hydrogen and oxygen generation
WO2012139017A1 (en) 2011-04-07 2012-10-11 Fenwal, Inc. Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates
US20140170159A9 (en) 2012-03-08 2014-06-19 Ge Wei Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
BR112016005526A2 (pt) 2013-09-12 2017-09-12 Halozyme Inc anticorpos receptores de fator de crescimento anti-epidérmido modificado e métodos de uso dos mesmos
CN106572991A (zh) 2014-06-11 2017-04-19 德克萨斯州大学系统董事会 用于克服铂耐受性的德克萨卟啉‑pt(iv)缀合物及组合物
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10335608B2 (en) 2016-04-20 2019-07-02 Theralase Technologies, Inc. Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
CN108586469B (zh) * 2018-03-19 2021-05-07 西北师范大学 一种抑制硫化镉光腐蚀的方法
JP2023547584A (ja) 2020-08-14 2023-11-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム マンガン化学療法、光音響イメージング、及び光温熱療法のためのテキサフィリン誘導体

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2308252A1 (de) * 1973-02-20 1974-08-22 Basf Ag Verfahren zur herstellung von mesotetraarylporphinen
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4613322A (en) * 1982-12-08 1986-09-23 Edelson Richard Leslie Method and system for externally treating the blood
JPS61275228A (ja) * 1985-03-14 1986-12-05 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド 治療用タンパク組成物中のビ−ルスの光動的不活性化
US4977177A (en) * 1985-04-30 1990-12-11 Nippon Petrochemicals Company, Ltd. Tetrapyrrole polyaminomonocarboxylic acid therapeutic agents
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4899755A (en) * 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
CA1315780C (en) * 1986-01-17 1993-04-06 Yozo Fukuda Porphyrin derivatives
US4915683A (en) * 1986-11-21 1990-04-10 The Medical College Of Wisconsin, Inc. Antiviral method, agents and apparatus
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US4878891A (en) * 1987-06-25 1989-11-07 Baylor Research Foundation Method for eradicating infectious biological contaminants in body tissues
US5250668A (en) * 1988-01-11 1993-10-05 Morgan Alan R Production and use of porphyrin derivatives and of compositions containing such derivatives
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5041078A (en) * 1989-03-06 1991-08-20 Baylor Research Foundation, A Nonprofit Corporation Of The State Of Texas Photodynamic viral deactivation with sapphyrins
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5256399A (en) * 1989-03-06 1993-10-26 Board Of Regents, The University Of Texas System Aromatic pentadentate expanded porphyrins in magnetic resonance imaging
US5272142A (en) * 1989-03-06 1993-12-21 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles and methods for treating tumors
US5162509A (en) * 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5257970A (en) * 1992-04-09 1993-11-02 Health Research, Inc. In situ photodynamic therapy

Also Published As

Publication number Publication date
WO1993014093A1 (en) 1993-07-22
FI943445A (fi) 1994-07-20
EP0623134B1 (en) 2002-11-06
US5439570A (en) 1995-08-08
NO301828B1 (no) 1997-12-15
NO942719D0 (no) 1994-07-20
US5569759A (en) 1996-10-29
US5504205A (en) 1996-04-02
CA2127530A1 (en) 1993-07-22
CA2127530C (en) 2001-05-29
DK0623134T3 (da) 2003-03-17
EP0623134A1 (en) 1994-11-09
JP3530529B2 (ja) 2004-05-24
US5432171A (en) 1995-07-11
US5451576A (en) 1995-09-19
ES2185627T3 (es) 2003-05-01
NZ246795A (en) 1996-02-27
DE69332469D1 (de) 2002-12-12
KR100286963B1 (ko) 2001-04-16
US5733903A (en) 1998-03-31
US5994535A (en) 1999-11-30
JPH07503009A (ja) 1995-03-30
AU3436793A (en) 1993-08-03
US5475104A (en) 1995-12-12
NO942719L (no) 1994-09-19
FI107157B (fi) 2001-06-15
DE69332469T2 (de) 2003-07-10
ATE227291T1 (de) 2002-11-15
US5252720A (en) 1993-10-12
PT623134E (pt) 2003-03-31
AU664877B2 (en) 1995-12-07

Similar Documents

Publication Publication Date Title
FI943445A0 (fi) Vesiliukoisten teksafyriinien metallikomplekseja
BG104056A (en) Triazole compounds and their use as dopamine-d3-ligands
DE69329112D1 (de) Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
EP0288534A4 (en) COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC.
BR9912327A (pt) Inibidores da uroquinase
ZA200500908B (en) Ruthenium anticancer complexes
MY164077A (en) Compositions and uses of et743 for treating cancer
NO178571C (no) Analogifremgangsmåte for fremstilling av et bifunksjonelt chelateringsmiddel
DE69633178D1 (de) Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
MX9301083A (es) Complejos de quelato y procesos para su preparacion.
DE60234930D1 (en) Farbstoff-sulfenate für die duale phototherapie
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO1998030585A3 (en) Use of pea3 in tumor suppression
DE59508960D1 (de) Haarbehandlungsmittel
NZ242748A (en) Compositions containing a pseudocatalase for treating depigmentation disorders
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
MX9700624A (es) Azolidinonas de imidazopiridina.
ATE353016T1 (de) Chelatiertes 8-hydroxychinolin zur behandlung von epithelialen verletzungen
WO2001030804A3 (en) Salt form of a conjugate useful in the treatment of prostate cancer
NO962221D0 (no) Anvendelse av dimeticon for behandling av konstipasjon
FI961339A0 (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa
BR9007080A (pt) Aplicacao de derivados de 1,2-benzopirona para o tratamento de tumores malignos no homem
ITMI920850A0 (it) Benzofurano-imidazoli per uso come inibitori di aromatisie 17,20-liasinella rpofilassi e trattamento del cancro della mammella e nell'iper- plasia prostatica benigna
UA9481A (uk) Засіб для профілактики і лікування вільнорадикального пошкодження органів і тканин